Monogenic Forms of Low-Renin Hypertension - Page 2 - Medscape
Figure 1. Familial hyperaldosteronism type I (also known as glucocorticoid-remediable aldosteronism). The genetic defect that causes this disorder is characterized by the presence of a hybrid or ...
Diagnosis of Primary Aldosteronism in a Patient - Page 4 - Medscape
Primary aldosteronism is caused in the majority of cases by an aldosterone-secreting adrenal adenoma or bilateral idiopathic hyperplasia. ... including glucocorticoid-remediable aldosteronism. ...
Monogenic Forms of Low-Renin Hypertension - Page 8 - Medscape
b Due to production of non-aldosterone mineralocorticoids. c Acquired forms due to DOC-producing tumors. d Due to increased activity of MCRs. e Acquired forms due to either licorice ingestion or ...
Monogenic Forms of Low-Renin Hypertension - Medscape
Seven single gene mutations are known to cause hypertension; this article guides clinicians through identification of the relatively uncommon defects, associated laboratory findings, and treatments.
Monogenic Forms of Low-Renin Hypertension - Page 5 - Medscape
Activating Mineralocorticoid Receptor Mutation Approximately 6% of pregnancies are associated with hypertension, and it is well established that hypertension in pregnancy increases the risk of ...
Monogenic Forms of Low-Renin Hypertension - Page 6 - Medscape
Syndrome of Apparent Mineralocorticoid Excess Both cortisol and aldosterone are potent activators of renal MCRs. In vitro, cortisol is a tenfold more potent activator of the MCR than aldosterone.
Monogenic Forms of Low-Renin Hypertension - Page 7 - Medscape
Liddle syndrome is an autosomal dominant disorder caused by hyperactivity of the amiloride-sensitive sodium channel (ENaC) of the principal cell of the cortical collecting tubule. In 1963, Liddle ...
Monogenic Forms of Low-Renin Hypertension - Page 4 - Medscape
a Due to hyperaldosteronism. b Due to production of non-aldosterone mineralocorticoids. c Acquired forms due to DOC-producing tumors. d Due to increased activity of MCRs. e Acquired forms due to ...
Updated Lupus Nephritis Guideline Advises Triple Therapy
2024年11月28日 · The glucocorticoid therapy in all patients with LN should begin with Pulse IV Therapy at 250-1000 mg/d for 1-3 days, followed by oral prednisone ≤ 0.5 mg/kg/d up to 40 mg/d, then tapered to a ...
B-Cell Depleting Drug Shines in IgG4-Related Disease - Medscape
2024年11月17日 · Excluding the 8-week glucocorticoid taper period, mean total glucocorticoid use was 1264.2 mg less in the inebilizumab than the placebo group, a significant reduction. Overall, 61 participants (90 ...